CFLAR and breast carcinoma: Since c-FLIP is a critical mediator of SMAC mimetic-resistance in cancer cells [15, 16], we hypothesized that suppression of c-FLIP by NCTD could sensitize breast cancer cells to Birinapant-mediated anticancer activity.